• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Viewpoints

Breakthrough treatments for the most neglected diseases: diversifying approaches is required to expand the development pipeline with new chemical entities

Home > Viewpoints

Breakthrough treatments for the most neglected diseases: diversifying approaches is required to expand the development pipeline with new chemical entities

28 Nov 2015
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

Graeme Bilbe

Viewpoint by

Graeme Bilbe, Research & Development Director, DNDi

Addressing the lack of patient-adapted treatments for those suffering from neglected diseases is no easy task. DNDi’s initial short-term strategies were designed to quickly provide improved treatments through new formulations or combinations of existing drugs, and/or improved treatment regimens. Six new treatments have been delivered since 2003.

The first of these were fixed-dose combinations of individually available antimalarial drugs, ASAQ and ASMQ – both transferred earlier this year to the Medicines for Malaria Venture – which are affordable, easy to administer, and able to withstand tropical conditions: each tablet contains a combination of two drugs given for 3 days. The mainstay treatment for Chagas disease, benznidazole, had no specific paediatric dosage form, so with partners we developed a child-adapted dosage form. NECT, for sleeping sickness (human African trypanosomiasis, HAT), has replaced the arsenic-based melarsoprol treatment – a drug so toxic it killed 1 in 20 patients. However, NECT still requires twice-daily injections of eflornithine over 7 days plus 10 days oral nifurtimox and needs to be administered by trained staff, with patients obliged to stay in hospital during the treatment period. Similarly, the combination of SSG&PM for visceral leishmaniasis in East Africa is better adapted to patients’ needs, but not ideal.

While all of these treatments were much-needed improvements, entirely new, effective, oral treatments, simple and safe enough to be administered at the primary healthcare level, are desperately needed. Discovering and developing such new chemical entities, or NCEs, has been the key challenge for DNDi in carrying out its long-term strategy, set out 12 years ago, and has led us to embark on various new pathways and partnership models to achieve our goals. While today’s pipeline for the most neglected diseases contains a significant number of NCEs in development, we have to continue exploring new ways to ensure the pipeline is systematically filled and replenished to ultimately ensure real breakthroughs in disease treatment.

The most advanced NCEs are for sleeping sickness, and have come from compound mining and the biotechnology industry

The goal is to develop one or two oral-only treatments, which will cure both the early (stage 1) and advanced, brain-form (stage 2) HAT. Fexinidazole came out of early compound-mining efforts involving massive literature research of pharmacological data on abandoned compounds, and testing of identified candidates for effectiveness in killing kinetoplastid parasites. Today, fexinidazole is in clinical development with Sanofi. Recruitment into the pivotal study to assess the efficacy and safety of oral fexinidazole in adults with stage 2 T.b. gambiense HAT was completed last year and patient follow-up is ongoing. Two complimentary studies began recruiting early in 2015 in children over 6 years of age, and in adults with early stage 2 or stage 1 HAT. In addition, further evidence on safety and effectiveness will be gathered from a larger group of patients in a Phase IIIb trial.

The second compound, SCYX-7158, is potentially a single-dose oral treatment. SCYX-7158 emerged from an optimization programme of an earlier compound identified through screening a library of benzoxaboroles from Anacor Pharmaceuticals. The improved SCYX-7158 is the first NCE to have come out of our lead optimization efforts and enter clinical development. It has completed evaluation in healthy human volunteers and preparations are underway for a trial in stage 2 T.b. gambiense HAT patients in early 2016.

Backup candidates have been developed in case of need, and support is given to other players in the field, notably the Novartis Institute for Tropical Diseases.

Filling the development pipeline for leishmaniasis and Chagas disease has proved to be a greater challenge, requiring multiple approaches

The development of treatments for the other kinetoplastid diseases has been more problematic, with studies highlighting the regional differences in response to treatments for visceral leishmaniasis (VL), and the lack of translation of drugs against Chagas disease from laboratory to patient. We are focusing on these diseases in multiple partnerships aimed at identifying NCEs with different mechanisms of action. In a long-term effort to tap into the diversity of compounds and therefore increase our ability to take drugs into testing in man, compound libraries from a variety of sources have been screened to identify ‘starting points’ for subsequent lead optimization, and identification of improved drug candidates. The earliest fruit of such approaches are for leismaniasis, including DNDI0690, a nitroimidazole class compound. In addition, a number of pre-clinical candidates is under investigation from an oxaborole-containing lead series, and other candidates from the aminopyrazole class, originally from Pfizer. The aminopyrazole class optimization work is in collaboration with Takeda through the GHIT fund. These and other new classes, like the pyrolopyrimidine class, are in optimization and illustrate the success of the long-term approach and the need for continued investment into accessing and screening novel compound libraries.

There are also two NCEs in development for cutaneous leishmaniasis (CL). Liposomal amphotericin B is effective in treating visceral leishmaniasis, but has some tolerability issues when taken systemically. A topical cream containing 3% amphotericin B, Anfoleish, is being developed as a short-term solution for cutaneous leishmaniasis, and is undergoing clinical trials in patients. In the longer term, CpG-D35 an adjunct therapy for CL and PKDL (post kala-azar dermal leishmaniasis) chemotherapies is being evaluated. It aims to stimulate the body’s immune response following chemotherapy.

The approach for filarial diseases is specific, based on drug repurposing and focused screening

There is a need for a safe, patient-adapted macrofilaricide to kill the adult worms that cause onchocerciasis and lymphatic filariasis. Drugs used in mass drug administration programmes kill the juvenile worms, but adults remain alive and can continue to reproduce and exacerbate disease. By screening small, focused, animal health compound libraries, we are more likely to identify effective compounds. Emodepside is very effective against filarial worms, and we are working in partnership with Bayer AG to develop a treatment for onchocerciasis. Alternative compounds are under evaluation with other organizations. Furthermore, we are screening so-called ‘repurposing libraries’, which contain approved drugs that may be useful in other disease areas – although high risk, if successful, this strategy can really speed up the drug development process, and thus reach patients faster.

Moving from bilateral to multilateral approaches can increase chances of high quality drug hits, engage cross-company research capacity, and reduce time and cost of early screening

Our approaches so far have been largely bilateral, but we are now exploring new multilateral ways of working with partners in order to increase research capacity whilst keeping costs at a minimum. Earlier this year DNDi launched its NTD Drug Booster. With funding from GHIT, the Booster aims to reduce the time and expense of screening millions of compounds for VL and Chagas. Four partners have joined the collaboration to date – Eisai Co Ltd, Shionogi & Co Ltd, Takeda Pharmaceutical Ltd, and AstraZeneca plc – and it is hoped that others will join in the future. Six initial ‘seed’ compounds have been issued so far. Screening results from our partners at the Institut Pasteur Korea on the first three have confirmed an improved action of these compounds to kill the parasite. In turn, these compounds will be resubmitted to the Booster for further analysis and refinement as part of the compound optimization process.

Open source drug discovery may tap into new potential, whilst building capacity and motivating young researchers in both endemic and non-endemic countries. A crowd-sourcing project is being planned, which will involve undergraduate medicinal chemistry students worldwide in an effort to optimize a drug candidate for one of our neglected diseases.

With the ongoing close collaboration with our partners and sustained engagement of funding partners, we continue to learn from the scientific approaches we have implemented to date, and will keep exploring new pathways to tackle the very specific and complex challenges of our target diseases. Today, with an increasingly diverse menu of approaches, we aim to deliver a new generation of treatments – safe, effective and easy enough to administer in the patients’ own environment – and look forward to the day when these deadly diseases see major R&D breakthroughs.

Graeme Bilbe, Research & Development Director, DNDi

Read, watch, share

Loading...
Patient with healthcare worker in hospital
Press releases
30 Mar 2023

Eumycetoma: DNDi welcomes Japan’s GHIT Fund support for registration of new treatment for deeply neglected fungal disease

Davide Paparo and Ian Hausler with their thermotherapy device "CLARA"
Stories
16 Mar 2023

Cutaneous leishmaniasis: Swiss students develop innovative thermotherapy device for safer treatment of ‘flesh-eating parasite’

Stories
8 Mar 2023

Highlighting gender-based treatment gaps on International Women’s Day: Mary Alamak’s story

DNDi-GARDP Southern Africa director, Carol Ruffell (left), presents the December 2022 edition of HIV Nursing Matters and the 2022 paediatric ARV dosing chart to Bénédicte Schutz, Monaco’s Director of International Cooperation (centre), and Yordanos Pasquier, Monaco’s Deputy Director of International Cooperation (right).
News
3 Mar 2023

Working together to ensure optimal treatment for children living with HIV in South Africa

Nurse with patient
Press releases
1 Mar 2023

Fiocruz and DNDi sign strategic alliance agreement

Statements
28 Feb 2023

DNDi’s submission to the Technical Assessment component of the first Global Stocktake

Statements
22 Feb 2023

DNDi comments on the zero draft of the WHO CA+ for consideration of the Intergovernmental Negotiating Body at INB4 & 5

Hat Platform Newsletter N°22 screenshot
Publications
22 Feb 2023

HAT Platform Newsletter No. 22

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo